Effects of Transcranial Direct Current Stimulation (tDCS) on Persistent Auditory Verbal Hallucinations in Schizophrenia

The Neural, Behavioural, and Cognitive Outcomes of Transcranial Direct Current Stimulation (tDCS) for Persistent Auditory Verbal Hallucinations in Schizophrenia

Many individuals with schizophrenia struggle with auditory verbal hallucinations (AVHs). In some cases, these AVHs can be resistant to medication treatment. Previous research has found that transcranial direct current stimulation (tDCS) can be helpful in treating symptoms in individuals with other psychiatric disorders, such as depression. This study will assess if tDCS is effective in treating AVHs in individuals with schizophrenia. tDCS is a non-invasive form of brain stimulation which uses a weak current to temporarily excite or inhibit underlying cortical regions with small electrodes placed on the scalp. tDCS has been found to improve mental processes, including attention and memory function. In addition to examining the effect of tDCS on AVHs, this study will assess the effects of tDCS on mood as well as brain electrical activity with electroencephalogram (EEG) recordings. As an additional component, participants will be invited to participate in neuroimaging. Using magnetic resonance imaging (MRI), brain activity and structure will be examined before and after tDCS. tDCS will be administered twice daily for 5 consecutive days for a total of 10 sessions. These study findings will contribute to the understanding of the impact of tDCS on AVHs, and will also increase knowledge of sound and memory/cognitive processing in individuals with schizophrenia.

Study Overview

• Status: Unknown
• Conditions: Auditory Hallucination, Verbal
• Intervention / Treatment: Device: Transcranial direct current stimulation (tDCS)

• Study Type: Interventional
• Enrollment (Anticipated): 84
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Ottawa, Ontario, Canada, K1Z7K4
      • Recruiting
      • Royal Ottawa Mental Health Centre
      • Sub-Investigator: Natalia Jaworska, PhD
      • Contact: Bronwen Schryver, B.Sc.; Phone Number: 6094 800-987-6424; Email: bronwen.schryver@theroyal.ca
      • Principal Investigator: Verner Knott, PhD, C.Psych

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 61 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Patients - Inclusion Criteria:

• Primary diagnosis of schizophrenia or schizoaffective disorder
• Clinically stable (discretion of psychiatrist)
• Consistent history of AVHs over the course of illness
• >3 AVHs per week
• Positive and Negative Syndrome Scale (PANSS) score of >3
• Primary medications limited to one of the atypical antipsychotics (medications stabilized for 4 weeks prior to enrollment)

Patients - Exclusion Criteria:

• Experiencing an acute psychotic episode
• Current drug/alcohol dependence
• Significant medical illness & mental retardation/learning disability
• Extra-pyramidal symptoms resulting in disordered movement
• Abnormal audiometric assessment (thresholds for pure tones >25 dB)
• History of significant neurological issues & head injuries/concussions resulting in loss of consciousness for >5 minutes

Healthy Controls - Inclusion Criteria:

• In good physical health
• No history of serious mental health issues

Healthy Controls - Exclusion Criteria:

• Personal history of psychiatric disorder
• Family history of schizophrenia in first degree relatives & history of mental health issues in first degree relatives that required extensive treatment or hospitalization
• Current/history of substance abuse
• Significant medical illness
• Extra-pyramidal symptoms resulting in movement disorder
• Abnormal audiometric assessment (thresholds for pure tones >25 dB)
• Significant neurological issues & head injuries/concussions resulting in loss of consciousness for >5 minutes

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Active tDCS; Administration of a 2 milliamp (mA) current delivered via two scalp electrodes for 20 minutes (ramp-in + ramp-out periods, 30s total) 2 times per day for 5 consecutive days, >3 hour interval between sessions, for a total of 10 tDCS sessions. tDCS will be administered with a constant current regulator (NeuroConn DC-Stimulator Plus®, Germany) using 2 saline-soaked sponge electrodes applied over the scalp. Using the 10-20 international EEG system for tDCS electrode placement, the anode will be positioned midway between F3 and Fp1 (left DLPFC) and the cathode midway between T3 and P3 (left TPJ).	Device: Transcranial direct current stimulation (tDCS); Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.
Sham Comparator: Sham tDCS; Administration of 2mA tDCS for 30 seconds followed by 19.5 minutes of no current via two scalp electrodes for 20 min (2X/day for 5 consecutive days) with >3 hours interval between sessions, for a total of 10 tDCS sessions.	Device: Transcranial direct current stimulation (tDCS); Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.
Other: Open-label Active tDCS; Subjects who have received sham tDCS will be given the option to subsequently receive 10 sessions of open-label active tDCS (2X/day for 5 consecutive days) with >3 hours interval between sessions, for a total of 10 tDCS sessions.	Device: Transcranial direct current stimulation (tDCS); Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.
No Intervention: Healthy Control; Healthy volunteers will complete the same questionnaires, EEG recording procedures, and neuroimaging scans as the schizophrenia patient group, but will not undergo tDCS.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in auditory hallucination severity measured by the Psychotic Symptom Rating Scale (PSYRATS)	The PSYRATS is a multidimensional measure of auditory hallucinations, including 11 items rated on five-point (0-4) scales (total score range 0-44). Symptoms are rated over the last week, with higher scores reflecting more severe symptoms. The dimensions assessed are frequency, duration, location, loudness, beliefs about origin, negative content, intensity of negative content, amount of distress, intensity of distress, disruption of life and control.	Baseline, after 2nd tDCS session on days 1, 3, and 5, and follow-up (within a week of completing tDCS)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Voice Power Differential Scale (VPDS) Scores	The Voice Power Differential Scale (VPDS) is a 7-item scale used to measure the perceived power differences between the voice and the voice hearer. Each item is rated on a five-point scale (1-5), with higher scores indicating greater power differential in favour of the voices, with total scores ranging from 7-35.	3 weeks (baseline to follow-up)
Change in Beliefs about Voices Questionnaire-Revised (BAVQ-R) Scores	The BAVQ-R is a 35-item questionnaire assessing people's beliefs about auditory hallucinations, and their emotional and behavioural reactions to them. All responses are rated on a 4-point scale: disagree (0); unsure (1); agree slightly (2); agree strongly (3), the measure thus assesses degree of endorsement of items. The scale consists of five subscales: malevolence (score range 0-18), benevolence (0-18), omnipotence (0-18), resistance (0-27), and engagement (0-24).	3 weeks (baseline to follow-up)
Change in Voices Acceptance and Action Scale (VAAS) Scores	The VAAS was developed to assess acceptance-based or action-based beliefs in response to auditory verbal hallucinations, in general and specifically to command hallucinations. This 31-item scale is divided into section A (i.e., 12 item stand-alone scale for general auditory hallucinations) and section B, referring specifically to command hallucinations. The participant is asked to rate their opinion from 1 'Strongly Disagree' to 5 'Strongly Agree', with higher scores meaning higher levels of acceptance and perception of acting according to one's valued life directions. Section A scores can range from 12-60, while section B scores can range from 19-95.	3 weeks (baseline to follow-up)
Change in Electroencephalography (EEG) - Resting-State Alpha Power	Changes in resting-state EEG power in alpha band. Resting-state recordings completed in both eyes-closed and eyes-open conditions, 5 minutes each.	3 weeks (baseline to follow-up)
Change in Electroencephalography (EEG) - Resting-State Beta Power	Changes in resting-state EEG power in beta band. Resting-state recordings completed in both eyes-closed and eyes-open conditions, 5 minutes each.	3 weeks (baseline to follow-up)
Change in Electroencephalography (EEG) - Resting-State Delta Power	Changes in resting-state EEG power in delta band. Resting-state recordings completed in both eyes-closed and eyes-open conditions, 5 minutes each.	3 weeks (baseline to follow-up)
Change in Electroencephalography (EEG) - Resting-State Theta Power	Changes in resting-state EEG power in theta band. Resting-state recordings completed in both eyes-closed and eyes-open conditions, 5 minutes each.	3 weeks (baseline to follow-up)
Change in Electroencephalography (EEG) - Resting-State Gamma Power	Changes in resting-state EEG power in gamma band. Resting-state recordings completed in both eyes-closed and eyes-open conditions, 5 minutes each.	3 weeks (baseline to follow-up)
Change in Electroencephalography (EEG) - Mismatch Negativity (MMN)	Change in MMN peak amplitudes and latencies to non-speech (tonal) deviants and speech (syllabic) deviants during the multi-feature optimal MMN paradigm.	3 weeks (baseline to follow-up)
Change in Electroencephalography (EEG) - P50	Change in T/C ratio (testing stimulus/conditioning stimulus) during paired click test. Change in T/C difference (testing stimulus - conditioning stimulus) during paired click test	3 weeks (baseline to follow-up)
Change in Brain Functional Magnetic Resonance Imaging (fMRI) - Resting-State	Changes in resting-state activity and connectivity within and between the auditory cortex and select regions of the default-mode network.	3 weeks (baseline to follow-up)
Change in Brain Functional Magnetic Resonance Imaging (fMRI) - Mismatch Negativity (tonal)	Changes in task-related activity and connectivity within and between the auditory cortex and select regions of the default-mode network .	3 weeks (baseline to follow-up)
Change in Brain Magnetic Resonance Spectroscopy (MRS)	Changes in glutamate/glutamine (Glu/Gln) concentrations in the auditory cortex.	3 weeks (baseline to follow-up)
Change in Cambridge Neuropsychological Test Automated Battery (CANTAB) Schizophrenia Battery	Changes in cognitive functioning abilities in core domains often affected in psychosis.	3 weeks (baseline to follow-up)
Change in Social Cognition - Social Attribution Task	Changes in social cognition/social inference abilities measured by a computerized social attribution task.	3 weeks (baseline to follow-up)

Collaborators and Investigators

• Sponsor: University of Ottawa
• Collaborators: The Royal Ottawa Mental Health Centre
• Investigators: Principal Investigator: Verner Knott, PhD, C.Psych, University of Ottawa; Principal Investigator: Natalia Jaworska, PhD, University of Ottawa

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2019
• Primary Completion (Anticipated): January 1, 2021
• Study Completion (Anticipated): January 1, 2021

Study Registration Dates

• First Submitted: April 15, 2019
• First Submitted That Met QC Criteria: January 6, 2020
• First Posted (Actual): January 10, 2020

Study Record Updates

• Last Update Posted (Actual): January 10, 2020
• Last Update Submitted That Met QC Criteria: January 6, 2020
• Last Verified: January 1, 2020

More Information

Terms related to this study

• Keywords: Schizophrenia; Cognition; EEG; Schizoaffective disorder; Transcranial direct current stimulation (tDCS); Brain imaging
• Additional Relevant MeSH Terms: Mental Disorders; Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Schizophrenia Spectrum and Other Psychotic Disorders; Perceptual Disorders; Schizophrenia; Hallucinations
• Other Study ID Numbers: 2017020

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No